and is the single most important cause of liver related death. 1, 2 Alcoholic liver disease has higher mortality than liver disease of any other etiology and while abstinence improves survival, this effect is most pronounced in early stages. 3, 4 Consequently, there is an urgent need to strengthen detection of advanced fibrosis in primary care and improve community methods for screening people at high risk, as this will allow for timely alcohol rehabilitation and future antifibrotic therapies. 5, 6 Although liver stiffness with transient elastography (TE) is well-validated for assessment of alcoholic liver fibrosis and cirrhosis, 7, 8 the method is costly, limited to referral liver centres and has a 5-10% failure rate. 9 Blood based markers are therefore of particular interest, as they can be applied in most clinical settings. 10 However, none of these markers are currently validated for detection of alcohol induced liver fibrosis. 11 The Enhanced Liver Fibrosis (ELF) test is a commercially available algorithm that combines three direct serum markers of extracellular matrix remodelling and fibrogenesis:
hyaluronic acid (HA), the N-terminal pro-peptide of collagen type III (PIIINP) and tissue inhibitor of metalloproteinase-1 (TIMP-1). 12, 13 ELF at a 10.5 cut-off value was recently recommended to detect advanced fibrosis in primary care patients at risk of non-alcoholic fatty liver disease (NAFLD). 14 The recommendation remains controversial, as it was based on a tertiary setting, pediatric NAFLD study. 15 Additionally, the diagnostic accuracy of ELF has never been compared head-to-head with elastography, competing patented fibrosis markers and indirect markers, which utilize routine biochemistry at a far lower cost.
We therefore aimed to validate ELF for the diagnosis of advanced alcoholic liver fibrosis in patients recruited from primary and secondary healthcare, using the 10.5 cut-off, but also manufacturer proposed cut-offs 9.8 and 7.7. 16, 17 Secondary aims were to assess the diagnostic accuracy of ELF for significant fibrosis and cirrhosis and whether combination of 
Patients
Patients from primary healthcare were recruited consecutively from two municipal alcohol rehabilitation centres and through a community call to screen for alcoholic liver disease.
We recruited secondary care patients through referrals to three outpatient hospital liver clinics in the Region of Southern Denmark. All patients consented in writing prior to inclusion. All patients were at a significant risk of fibrogenic alcoholic liver disease that justified performing a liver biopsy, except 15 patients included in 2016 with liver stiffness below 6.0 kPa. We did not perform a liver biopsy in these patients, because our data published January 2016 showed a negative predictive value of 100% for advanced fibrosis if TE was below 6.0 kPa. 7 This rendered the diagnostic value of a liver biopsy negligable and we therefore revised the study protocols' biopsy criteria. In the analyses, these patients were considered as being free of advanced fibrosis, but with otherwise unknown fibrosis stage.
We recruited patients with a history of excessive use of alcohol for more than one year (>24 grams/day for women and >36 grams/day for men), age 18-75 years and informed consent to undergo a liver biopsy. We revised the age criteria three years after study
initiation, because no patient below 30 years of age included in that period had advanced fibrosis. 7 Exclusion criteria were decompensated liver disease with clear signs of cirrhosis, concurrent liver disease other than alcoholic, severe alcoholic hepatitis, debilitating disease with an expected survival of less than one year, hepatic congestion or cholestasis evidenced by ultrasound, or inability to comply with the study protocol.
All investigations were performed on the same day, according to standard operating procedures, with the patient in a fasting state.
Alcohol history
Patients gave report on their alcohol history according to standard questionnaires, which detailed the duration and magnitude of the overuse, peak alcohol consumption, current drinking and, if abstinent, duration of abstinence prior to inclusion. We also used the AUDIT (Alcohol Use Disorders Identification Test) and CAGE (Cut back, Annoyed, Guilty and Eye-opener) questionnaires to assess drinking pattern and alcohol dependency. 19, 20 
Non-invasive liver fibrosis investigations
We measured the ELF test (Siemens Healthcare Diagnostics Inc., USA) on an Advia
Centaur XP (Siemens Healthcare Diagnostics Inc., USA) according to manufacturer instructions. Coefficient of variation estimated from the assay controls with three different concentrations ranged from 4.1% to 6.1% for HA; from 4.0% to 5.4% for PIIINP and from 2.5% to 2.9% for TIMP-1.
We used a 10.5 cut-off, convenience adjusted from 10.51 as recommended by the National Institute for Health and Care Excellence (NICE) for advanced fibrosis in NAFLD. 14, 15 We also considered the manufacturer recommended 9.8 and 7.7 cut-offs; the first to diagnose advanced fibrosis (≥F3), the latter to exclude significant fibrosis (≥F2). 16, 17 M A N U S C R I P T
In posthoc analyses we compared ELF with FibroTest (Biopredictive Paris, France).
FibroTest is a commercially available algorithm that combines age, gender, alpha-2macroglobulin, haptoglobin, apolipoprotein, bilirubin and GGT. 21 We used the 0.58 manufacturer recommended cut-off for ≥F3.
One experienced nurse operator (>500 scans) performed liver stiffness measurements by transient elastography (TE) using a FibroScan 502 Touch (Echosens, France) according to standard. 22, 23 An ultrasound-trained investigator (>300 scans per year) performed abdominal ultrasonography and 2-dimensional shear-wave elastography (2D-SWE) with
the Aixplorer system (Supersonic Imagine, France) according to published standards. 22, 24 As recommended by the 2015 Baveno VI consensus paper, we considered TE ≥15.0 kPa as optimal for diagnosing advanced fibrosis. 25 In post-hoc analyses, we checked whether the 15.0 kPa cut-off was appropriate for our cohort, given that alcoholic liver disease may yield higher liver stiffnesses than other etiologies. 11 The optimal cut-off for ≥F3 for TE was 15.5. We also evaluated our previously published optimal cut-offs for cirrhosis; 19.7 kPa for TE and 16.4 kPa for 2D-SWE. 7 Finally, we evaluated six indirect indices of liver fibrosis, available from routine biochemical analyses: The AST-platelet-ratio index (APRI), age-platelet index (AP index), fibrosis-4 index (FIB-4), Forns index, AST:ALT ratio and GGT-to-platelet ratio (GPR). Algorithms used to calculate each index are listed in the appendix. We used literature based optimal cut-offs for the diagnosis of advanced fibrosis: APRI ≥1.0, AP index ≥6.0, FIB-4 ≥3.25, Forns index ≥6.8, AST:ALT ratio >1.0 and GPR ≥0.32. [26] [27] [28] [29] [30] [31] [32] For the sequential diagnostic strategy, we used a rule-out cut-off for Forns of 4.1, corresponding to 6% or lower predicted probability of advanced fibrosis.
Histological liver fibrosis staging
We performed a percutaneous liver biopsy with a 17G Menghini suction needle (Hepafix, Braun, Germany). One experienced pathologist described all liver biopsies blinded to the patient's results. Biopsy quality assessment in the absence of cirrhosis included >10 mm length and >5 portal tracts. We staged liver fibrosis according to Kleiner, which has been proposed as the best scoring system for alcoholic liver fibrosis 33 : F0 is no fibrosis, F1 is portal or periportal fibrosis only, F2 is perisinusoidal fibrosis in combination with portal or periportal fibrosis, F3 is bridging fibrosis and F4 is cirrhosis. 34 We also assessed liver histology according to the nonalcoholic fatty liver disease activity score (NAS-CRN) for steatosis (0-3), ballooning (0-2) and lobular inflammation (0-3). 34 A composite score for inflammatory activity consisted of the sum of ballooning and lobular inflammation (0-5).
Statistical analyses
Summary data are reported as medians and interquartile ranges (IQR) or counts and frequencies, with Wilcoxon rank sum test to report between-group comparisons.
We evaluated the discriminative accuracy of non-invasive tests using area under the receiver operating characteristics curve (AUROC) with calculation of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the predefined cutoff values listed above. The DeLong test was used for AUROC comparisons. Diagnostic testing included per-protocol and intention-to-diagnose analyses, treating failed measurements as false positives or false negatives, depending on histological fibrosis stage. 35 We summarised the calibration of tests using the Brier score, Hosmer-Lemeshow goodness-of-fit test with 10 quantiles and observed/expected calibration plots.
M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 12 We investigated the following potential predictors of ELF, FibroTest and elastography in multivariable linear regression with backwards, step-wise elimination: fibrosis stage, steatosis score, histological inflammatory activity (sum of NAS-CRN subscores for ballooning and lobular inflammation), gender, age, body mass index (BMI), drinks per day up to inclusion, ALT, AST, alkaline phosphatase, bilirubin, GGT. We chose the predictors that prior publications suggested may influence ELF and other non-invasive tests. 9, 17, 36 Finally, we used the net reclassification index to test whether there was any incremental value of using ELF instead of, or in combination with, other fibrosis markers. 37 We analysed the net reclassification for ELF versus indirect serum indices in patients recruited from primary healthcare; and of ELF versus transient elastography in patients recruited from secondary healthcare.
A P-value of 0.05 was considered statistically significant. We used STATA 15 (Statacorp, TX, US) for the statistical analyses. The syntax is available upon request.
RESULTS

Patients
Between May 2013 and August 2016 we included 289 patients; 128 from primary care and 161 from secondary care (table 1) . See appendix for the study flow (figure S1).
We successfully measured ELF and the indirect serum indices in all patients, while
FibroTest failed in four patients due to unusually low haptoglobin (one) or unusually high apolipoprotein A1 (three). TE was unreliable in six patients, failed in seven and was not available due to equipment maintenance in another seven. As we acquired the equipment for 2D-SWE after study initiation, 2D-SWE measurements were missing in 20 patients, while we failed to obtain valid measurements in four patients.
Histology
The liver biopsy procedure caused major, non-fatal, biopsy-related bleeding in two patients with cirrhosis, requiring intervention. 
Predictors of ELF, FibroTest and elastography
Fibrosis stage and NAS-CRN activity subscore were the strongest predictors of ELF, 
ELF versus other non-invasive markers of liver fibrosis
ELF outperformed all of the six indirect serum indices of fibrosis, but not FibroTest (table 2 and appendix, figure S4 ). There was however no added diagnostic value of combining Both TE and 2D-SWE diagnosed advanced fibrosis with higher accuracy than ELF and FibroTest in per-protocol analysis, but not in intention-to-diagnose analyses (table 2) .
Per-protocol analyses use of TE instead of ELF led to a net reclassification of 16% (9/58) of patients with advanced fibrosis and 5% (11/211) of patients without advanced fibrosis (figure 3). TE and ELF in combination did not have a higher diagnostic accuracy than TE alone, nor did it increase classification of patients (combined AUROC = 0.96; 95% CI 0.94-0.99; P=.157 for comparison with TE alone; net reclassification index -0.032 ±0.031;
P=0.309). This was also the case when looking only at 26 patients with discordant results:
In patients with ELF<10.5 but TE≥15 kPa, 75% (9/12) had advanced fibrosis. And in patients with ELF≥10.5 but TE<15 kPa, 100% (14/14) did not have advanced fibrosis.
There was similarly no added effect of combining TE with any other of the serum markers (data not shown).
A proposed sequential decision making tool for primary care
Based on the above findings, we formulated a post-hoc sequential strategy to stratify patients from primary care according to their risk of advanced fibrosis. The aim was to avoid referral of primary care alcohol overusing patients without advanced fibrosis for further liver investigations, to ensure optimal utilisation of resources ( figure S5 ).
For the 128 primary healthcare patients we first calculated the predicted probability of advanced fibrosis with an indirect serum index. In our case we used the Forns index as exemplar. We disregarded further investigations if the predicted probability was below the 
DISCUSSION
In this study, we have found the ELF test to be an efficient diagnostic tool to assess patients with alcohol overuse for advanced liver fibrosis with excellent discrimination and calibration in both primary and secondary healthcare. Our results support use of a 10.5 cut-off value, similar to the NICE recommendation for non-alcoholic fatty liver disease. ELF was not statistically different from FibroTest or elastography in intention-to-diagnose analyses, but elastography was superior to all serum fibrosis markers in per-protocol, after excluding failures and unreliables.
Our findings may provide a basis for a more effective care pathway for excess drinkers at risk of alcoholic liver fibrosis. Routine use of indirect serum fibrosis indices followed by ELF or FibroTest test in primary healthcare could exclude alcohol overusing patients, who do not have advanced liver fibrosis, from further futile investigations and over-diagnosis.
However, in a low prevalence population and because of spectrum bias, diagnostic tests will rarely be able to rule in disease, as evidenced by low positive predictive values for both ELF and FibroTest. Systematic detection of advanced fibrosis in patients with alcohol use disorders is therefore still an unmet need. 38 The wide availability and low cost of indirect markers based on routine blood tests favors them as first line decision tools, to identify patients in need of further, in-depth investigations in a sequential combination of diagnostic tests. Indeed, our proposed strategy was able to exclude at-risk patients from primary care with a very low probability of having advanced fibrosis, thus saving the costs of a commercial serum test and of referrals to secondary care hospitals. Our strategy saved 45 ELF tests per 100 primary care patients, compared to a test-all approach.
In our study, ELF, FibroTest and the indirect algorithms performed better than published results for serum fibrosis markers in advanced alcoholic fibrosis. 39, 40 One explanation may be the inclusion of patients with lower degree of hepatic inflammation and less biochemical
evidence of acute alcoholic liver injury than previous studies. [40] [41] [42] While drinking pattern did not predict ELF, FibroTest or elastography in our study, other studies indicate that active alcohol abuse may increase risk of false positives. 17, 36 However, our biopsy-controlled data suggest that hepatic inflammation and cholestatic liver injury influence the noninvasive markers, rather than alcohol in it self. Fibrosis stage, histological inflammation, alkaline phosphatase and bilirubin independently predicted both ELF, FibroTest and elastography. For ELF, one should also be cautious in patients older than 60 or younger than 30 years. Joint predictors of false positives may also explain why adding a serum marker to elastography did not result in significantly increased diagnostic accuracy.
Recent guidelines endorse synchronous combination of TE with a blood-based marker and looking at concordant versus discordant results. 23 We were not able to validate this method, as our data indicated a higher accuracy of TE, even in the discordant results. This finding also highlights measurement failures as a central disadvantage of ultrasound elastography and will hopefully motivate clinicians to push for obtaining reliable TE results, even in patients who fail at the first attempt. 43 A key advantage of our study is the inclusion of a large cohort of patients recruited from primary care, which strengthens the generalizability of our results. Additionally, we did not exclude patients with markers of the metabolic syndrome or ongoing drinking, which also reflects real-life patients.
In conclusion, the Enhanced Liver Fibrosis test and FibroTest are highly accurate serum markers to assess patients with a prior or current alcohol overuse for advanced fibrosis.
While ultrasound elastography has higher diagnostic accuracy if a reliable measurement can be obtained, serum markers may be more accessible to primary and secondary care. 1 Brier score is a measure of calibration, i.e. the disagreement between the observed fibrosis stage and the predicted presence of fibrosis a non-invasive test. A Brier score of 0.250 corresponds to a coin-toss (high disagreement), while a Brier score of 0.00 corresponds to a perfect test (highest possible agreement). 2 Intention-to-diagnose analysis for FibroTest based on 285 reliable measurements and 4 failures coded as false positive. 3 Intention-to-diagnose analysis for TE based on 269 reliable measurements, 6 unreliable measurements and 7 failures coded as false positive (n=3) and false negative (n=4). Seven cases where equipment was unavailable due to maintenance were not included in intention-to-diagnose analysis. 4 Enhanced liver fibrosis test Enhanced liver fibrosis test We suggested initial evaluation of primary care patients with an indirect fibrosis index (Forns index 
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Liver-Fibro STARD checklist
The Liver-FibroSTARD checklist summarizes the important information that must be present in the manuscripts of diagnostic studies on non-invasive tools for liver fibrosis evaluation. Compared to STARD, the Liver-FibroSTARD checklist includes 2 additional items (#12 and #26) and 44 sub-items. The sub-items correspond to those proposals that clearly depicted, within the items, each of the particular features of diagnostic studies on liver fibrosis tests. Finally, Liver-FibroSTARD presents as a complementary module of the STARD checklist.
Some items or sub/items include several criteria; major criteria are indicated by an asterisk (*). Example: item #3: "The study population: The inclusion and exclusion criteria*, setting, and locations* where data were collected". If a major item is missing, the corresponding criterion has to be rated absent. Some items/sub-items (#12.1 and #23.1, #13.10 and #22.2) are redundant since they can be found in different locations of the article.
TITLE/ABSTRACT/KEYWORDS
1. Identify the article as a study of diagnostic accuracy (recommend MeSH heading "sensitivity and specificity").
Identify the article, especially in the title, as a study of the diagnostic performance of liver fibrosis/cirrhosis biomarker(s)/test(s).
Cover page
1.2.
Recommended key words (choose the most appropriate): "liver fibrosis", "cirrhosis", "diagnosis", "biomarker", "diagnostic test", "noninvasive diagnosis".
INTRODUCTION
State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.
In study aims, specify:
If the aim is to identify new marker(s)/develop new test(s), or to evaluate published marker(s)/test(s).
Validation of published markers.
Whether the study is performed in a single or multiple cause(s) of chronic liver disease.
Single-etiology 17. The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard*; describe why participants failed to undergo either test (a flow diagram is strongly recommended).
Page 12 and Figure S1 17. 18. Time-interval* between the index tests and the reference standard, and any treatment administered between. Same-day index and reference
Distribution of severity of disease (define criteria) in those with the target condition*; other diagnoses in participants without the target condition.
All compensated, asymptomatic (see inclusion and exclusion criteria). MELD-Na, Table 1 19. 
